SCHEMBL3762902

SCHEMBL3762902

CC(Oc1ccc(Cl)cc1Cl)C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 4/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPT P10636 4/20 0.53
NPSR1 Q6W5P4 3/20 0.52
LMNA P02545 2/20 0.52
ALOX12 P18054 2/20 0.52
HTT P42858 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.45
HRH3 Q9Y5N1 5/20 0.44
F10 P00742 1/20 0.43
HPGD P15428 3/20 0.42
TSHR P16473 2/20 0.42
GAA P10253 1/20 0.42
TP53 P04637 1/20 0.42
SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3779475 0.89 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL3767725 0.86 HRH3 (0.49) SMN1; SMN2ALDH1A1KMT2AMAPTNPSR1
SCHEMBL3773850 0.86 MEN1 (0.47) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL3769174 0.83 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL3767951 0.82 MEN1 (0.55) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL3767216 0.80 KDM4E (0.52) ALDH1A1KMT2AMAPTNPSR1HTT
SCHEMBL3766137 0.80 LMNA (0.48) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL3773594 0.78 CCR3 (0.52) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL3770890 0.78 HRH3 (0.50) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL3769777 0.78 KDM4E (0.52) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 SMN1; SMN2 4282/4885ALDH1A1 1210/4885MEN1 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.